Solid Biosciences doses first participant in Phase 1b FALCON trial on SGT-212

Solid Biosciences (SLDB) announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical trial evaluating SGT-212. Bo Cumbo, President & CEO of Solid Biosciences, commented: “Initiating dosing in the FALCON trial represents the culmination of years of dedicated work towards moving the needle for the FA community. By aiming to precisely target the key structures responsible for neurologic morbidity and cardiac manifestations, we intend to address both quality-of-life and mortality drivers in this devastating disease, a key differentiation of SGT-212 when compared to potential alternatives. The dual-route administration strategy employed by SGT-212 exemplifies Solid’s mission to be bold in our vision, audacious in our science and steadfast in our commitment to bringing potentially life-changing medicines to patients.”